Elsevier

Psychiatry Research

Volume 64, Issue 3, 16 October 1996, Pages 147-159
Psychiatry Research

Article
Effects of meta-chlorophenylpiperazine on neuroendocrine and behavioral responses in male schizophrenic patients and normal volunteers

https://doi.org/10.1016/S0165-1781(96)02917-4Get rights and content

Abstract

Functional alterations in the central serotonergic system, including presynaptic and postsynaptic function, have been reported in schizophrenia. Recently, there have been conflicting reports that the increase in plasma cortisol or prolactin concentrations induced by meta-chlorophenylpiperazine (mCPP) was significantly blunted in schizophrenic patients compared with normal volunteers. Studies of the behavioral effects of mCPP, a serotonin (5-HT) receptor partial agonist with high affinity for 5-HT1c binding sites, have also yielded conflicting results in schizophrenic patients. The purpose of this study was to examine plasma levels of prolactin and cortisol, body temperature, and behavioral responses to mCPP and placebo in a single-blind study in 25 schizophrenic and 15 normal men. No differences either between schizophrenic patients and normal volunteers or between paranoid and undifferentiated/residual subtypes of schizophrenia were found in mCPP-induced prolactin, cortisol, or temperature responses. Schizophrenic patients and normal volunteers reported significant increases in feeling calm and feeling strange of comparable magnitude following mCPP. No significant differences between normal volunteers and schizophrenic patients were found in post-mCPP behavioral ratings, such as anxiety, irritability, depression, restlessness, or arousal.

References (59)

  • R.S. Kahn et al.

    Serotonin function in schizophrenia: Effects of meta-chlorophenylpiperazine in schizophrenic patients and healthy subjects

    Psychiatry Res

    (1992)
  • R.S. Kahn et al.

    m-Chlorophenylpiperazine as a probe of serotonin receptors: A review

    Biol Psychiatry

    (1991)
  • G.A. Kennett et al.

    Anxiogenic-like effects of m-CPP and TFMPP in animal models are opposed by 5-HT1c receptor antagonists

    Eur J Pharmacol

    (1989)
  • B. Lerer et al.

    Neuroendocrine responses in chronic schizophrenia: Evidence for a serotonergic dysfunction

    Schizophr Res

    (1988)
  • M.T. Lowy et al.

    Stimulation of serum cortisol and prolactin secretion in man by MK-212, a centrally active serotonin agonist

    Biol Psychiatry

    (1988)
  • H.Y. Meltzer et al.

    Effect of pindolol pretreatment on mCPP-induced plasma cortisol and prolactin responses in normal men

    Psychiatry Res

    (1995)
  • T. Mita et al.

    Decreased serotonin S2 and increased dopamine D2 receptors in chronic schizophrenics

    Biol Psychiatry

    (1986)
  • P. Preziosi et al.

    Effects of naloxone on the secretion of prolactin and corticosterone induced by 5-hydroxytryptophan and a serotonergic agonist, mCPP

    Life Sci

    (1983)
  • L.H. Price et al.

    Clinical studies of 5-HT function using i.v. l-tryptophan

    Prog Neuropsychopharmacol Biol Psychiatry

    (1990)
  • R. Ranjan et al.

    Effect of MK-212, a centrally acting serotonin agonist, on prolactin, cortisol and body temperature in schizophrenia

    Biol Psychiatry

    (1995)
  • J.P. Seibyl et al.

    Effects of ritanserin on the behavioral, neuroendocrine, and cardio-vascular responses to m-CPP in healthy human subjects

    Psychiatry Res

    (1991)
  • P. Thompson et al.

    Use of placebo controlled models in neuroendocrine challenge studies in psychiatric research

    Psychiatry Res

    (1994)
  • L.N. Yatham et al.

    Minireview. Neuroendocrine probes of serotonergic function: A critical review

    Life Sci

    (1993)
  • American Psychiatric Association
  • R.C. Arora et al.

    Serotonin 2 (5-HT2) receptor binding in the frontal cortex of schizophrenic patients

    J Neural Transm

    (1991)
  • G. Bagdy et al.

    Different serotonin receptors mediate blood-pressure, heart rate, plasma catecholamine and prolactin responses to m-chlorophenylpiperazine in conscious rats

    J Pharmacol Exp Ther

    (1989)
  • J.P. Bennett et al.

    Neurotransmitter receptors in frontal cortex of schizophrenics

    Arch Gen Psychiatry

    (1979)
  • A. Bleich et al.

    The role of serotonin in schizophrenia

    Schizophr Bull

    (1988)
  • D. Ceulemans et al.

    Effects of serotonin antagonism in schizophrenia: A pilot study with setoperone

    Psychopharmacology

    (1985)
  • Cited by (19)

    • Serotonin and schizophrenia

      2020, Handbook of Behavioral Neuroscience
      Citation Excerpt :

      m-CPP increases anxiety, body temperature, and plasma levels of prolactin, cortisol, GH, and ACTH, but does not provoke psychotic symptoms in healthy human volunteers (Breier, 1995). Schizophrenia patients show either blunted (Iqbal et al., 1991; Maes & Meltzer, 1996) or normal prolactin responses to m-CPP (Kahn et al., 1992; Krystal et al., 1993). Moreover, m-CPP has been reported to exacerbate (Abi-Saab et al., 2002; Iqbal et al., 1991; Krystal et al., 1993), reduce (Kahn et al., 1992), or have no effect on psychotic symptoms (Breier, Kirkpatrick, & Buchanan, 1993; Koreen, Lieberman, Alvir, & Chakos, 1997; Owen et al., 1993).

    • Decreased serotonin<inf>2C</inf> receptor responses in male patients with schizophrenia

      2015, Psychiatry Research
      Citation Excerpt :

      We found no relation between the temperature responses and body mass index (data not presented). The decreased behavioral response to MK-212 in patients with SCH is in contrast to our prior report in a small sample with MK-212 (Lee et al., 1992), and with m-CPP using 0.5 mg/kg (Maes and Meltzer, 1996), which did not show significant difference in behavioral responses between groups. The main reasons may likely to be sample size, the greater specificity of MK-212 for 5-HT2C receptors than m-CPP, and the dosage of m-CPP used.

    • Rethinking responsibility in offenders with acquired paedophilia: Punishment or treatment?

      2015, International Journal of Law and Psychiatry
      Citation Excerpt :

      Many factors have been postulated to indicate that individuals with paedophilia may have neurodevelopmental or neurochemical impairments (De Ridder, Langguth, Plazier, & Menovsky, 2009). Neurochemical findings show that individuals with developmental paedophilia may have a serotonergic disturbance, most likely caused by the decreased activity of the presynaptic serotonergic neurons and hypersensitivity of the serotonin 2 postsynaptic receptors (Maes & Meltzer, 1996; Maes et al., 2001). Previous reports (Moller & Bier-Weiss, 1995) have shown that disorders in serotonin metabolism and increased sympathoadrenal system activity are related to aggression or violence and impulse control disorder.

    • Serotonin and Schizophrenia

      2010, Handbook of Behavioral Neuroscience
    • 6 5-HT<inf>2C</inf> Ligands: Recent Progress

      2008, Progress in Medicinal Chemistry
      Citation Excerpt :

      One potential issue for this approach to the treatment of schizophrenia is the observation of mixed effects with the non-selective 5-HT2C receptor agonist m-chlorophenylpiperazine (mCPP) (8) in clinical studies on schizophrenics. While Kahn et al.[110] reported that low oral doses of mCPP decreased psychotic symptoms, others reported that either it caused only non-specific effects, such as feeling calm [111, 112], or that it mildly increased positive symptoms without effect on negative symptoms [113, 114]. The exacerbating action of mCPP on positive symptoms was reportedly reversed by pretreatment with the 5-HT2A and 5-HT2C receptor antagonist, ritanserin [115].

    View all citing articles on Scopus
    View full text